Cancer Links (@linkscancer) 's Twitter Profile
Cancer Links

@linkscancer

🧬Sharing #CancerResearch, news, and breakthroughs. Links & Retweets 📰✨ #CancerAwareness #CancerSupport 💪💜

ID: 1664653629179953154

calendar_today02-06-2023 15:22:22

5,5K Tweet

239 Followers

727 Following

Matteo Lambertini, MD PhD (@matteolambe) 's Twitter Profile Photo

Live from #ESMOBreastBCY…just got a couple of very precious gifts from my mentor & hero Ann Partridge MD, MPH ❤️ GRAZIE MILLE for what you have done for young #BreastCancer community & #oncology fellows !!! ESMO - Eur. Oncology OncoAlert #ESMOBreast25 #ESMOambassadors Dana-Farber’s Breast Oncology Center Dana-Farber

Live from #ESMOBreastBCY…just got a couple of very precious gifts from my mentor &amp; hero <a href="/AnnPartridgeMD/">Ann Partridge MD, MPH</a> ❤️
GRAZIE MILLE for what you have done for young #BreastCancer community &amp; #oncology fellows !!!

<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/OncoAlert/">OncoAlert</a> #ESMOBreast25 #ESMOambassadors <a href="/DFCI_BreastOnc/">Dana-Farber’s Breast Oncology Center</a> <a href="/DanaFarber/">Dana-Farber</a>
Jarushka Naidoo (@drjnaidoo) 's Twitter Profile Photo

Final Analysis Ph I CHRYSALIS: Amivantamab in stage IV METexon14+ JTO & JTO CRR: - 97pts (1L=16; 2L=28, prior MET TKI=53) - ORR (all-comer) 32%, 50% in 1L, 19% prior MET TKI - mDOR 11.2m; mPFS 5.3m; mOS 15.8m - 79% rash, 72% IRRs OncoAlert #LCSM jto.org/article/S1556-…

Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Still too much ADT alone… In this VA study of 6216 veterans with de novo mHSPC: 📅 2022... and still 37% got only ADT! 🔵Combo therapy = longer OS (40.3 vs 33.0 mo) 🔵Not only biology, also delivery does matter! JAMA Network Open OncoAlert Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation

Still too much ADT alone…
In this VA study of 6216 veterans with de novo mHSPC:
📅 2022... and still 37% got only ADT!
🔵Combo therapy = longer OS (40.3 vs 33.0 mo)
🔵Not only biology, also delivery does matter!
<a href="/JAMANetworkOpen/">JAMA Network Open</a> <a href="/OncoAlert/">OncoAlert</a> <a href="/APCCC_Lugano/">Advanced Prostate Cancer Consensus Conference</a> <a href="/PCFnews/">Prostate Cancer Foundation</a>
Yakup Ergün (@dr_yakupergun) 's Twitter Profile Photo

Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer Should we recommend adjuvant therapy in T1a–T1b tumors? Great review👇 nature.com/articles/s4152…

Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer

Should we recommend adjuvant therapy in T1a–T1b tumors?

Great review👇

nature.com/articles/s4152…
Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo

Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials - both w OS improvement!) PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.

Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant &amp; metastatic trials - both w OS improvement!)

PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.
Matteo Lambertini, MD PhD (@matteolambe) 's Twitter Profile Photo

Last post from #ESMOBreast25…I’m deeply grateful & really honored for the opportunity to chair together with Dr. Shani Paluch-Shimon the #ESMOBreastBCY sessions…2 days that have brought together the #oncology community caring for #BreastCancer in young women! ESMO - Eur. Oncology OncoAlert

Last post from #ESMOBreast25…I’m deeply grateful &amp; really honored for the opportunity to chair together with Dr. Shani Paluch-Shimon the #ESMOBreastBCY sessions…2 days that have brought together the #oncology community caring for #BreastCancer in young women!
<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/OncoAlert/">OncoAlert</a>
Drew Moghanaki (@drewmoghanaki) 's Twitter Profile Photo

Just when you thought the horizon for locally advanced NSCLC couldn’t get brighter… along comes HORIZON-01: ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib. Thanks Millie Das MD for the heads up. #ATS2025 #RadOncMeetsTargetedTherapy

Just when you thought the horizon for locally advanced NSCLC couldn’t get brighter… along comes HORIZON-01: ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib. 

Thanks <a href="/DasMillie11/">Millie Das MD</a> for the heads up. #ATS2025 #RadOncMeetsTargetedTherapy
Donjeta Zeqa (@donjetazeqa) 's Twitter Profile Photo

Back home after an amazing #ESMOBreast25 Grateful to speak in two panels on BRCA mutations & IBC. Honored to share the stage with such brilliant experts. Let’s keep pushing for better care🩷 ESMO - Eur. Oncology Wendy Woodward MDPhD Breast Surgeon Europa Donna Europa Donna Albania OncoAlert

Back home after an amazing #ESMOBreast25

Grateful to speak in two panels on BRCA mutations &amp; IBC. Honored to share the stage with such brilliant experts. 

Let’s keep pushing for better care🩷 <a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/IBCradiation/">Wendy Woodward MDPhD</a> <a href="/naren_basu/">Breast Surgeon</a> <a href="/EuropaDonnaEUR/">Europa Donna</a> <a href="/EuropaDonnaAl/">Europa Donna Albania</a> <a href="/OncoAlert/">OncoAlert</a>
Hidehito HORINOUCHI (@hhorinouchi) 's Twitter Profile Photo

🔥 Annals of Oncology 🆙 ✅ Collection of articles from Japanese authors 🎯This collection includes the winner of the JSMO 2025 Award, junko tanizaki 🎯Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary OncoAlert annalsofoncology.org/content/jsmo

🔥 <a href="/Annals_Oncology/">Annals of Oncology</a>  🆙
✅ Collection of articles from Japanese authors 
🎯This collection includes the winner of the JSMO 2025 Award, <a href="/JunTanizaki3/">junko tanizaki</a>
🎯Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
<a href="/OncoAlert/">OncoAlert</a>
annalsofoncology.org/content/jsmo
Lei Deng, MD (He/Him) (@leideng3) 's Twitter Profile Photo

❓What H/O programs sponsor What visas❓ This year, Dr. Xia (Yaya) Wu Tufts University spearheaded a Visa project to survey this for IMG applicants! Stay tuned for data release from Visa and Advocacy Committee on 5/30 IMG Oncologists Hem-Onc Fellows Network #ASCO25 #IMGoncCoP

Enrique Grande (@drenriquegrande) 's Twitter Profile Photo

⚡️ Identification of a panel of lncRNAs derived from urinary extracellular vesicles as non-invasive diagnostic biomarkers for bladder cancer #BladderCancer sciencedirect.com/science/articl….

⚡️ Identification of a panel of lncRNAs derived from urinary extracellular vesicles as non-invasive diagnostic biomarkers for bladder cancer 

#BladderCancer 

sciencedirect.com/science/articl….
Dana-Farber’s Breast Oncology Center (@dfci_breastonc) 's Twitter Profile Photo

Here’s the most recent #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (May 12th-18th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Here’s the most recent #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (May 12th-18th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
Jun Gong (@jgong15) 's Twitter Profile Photo

Huge congrats to Cancer at Cedars-Sinai 2nd yr heme/onc fellow Dr. Louisa Liu for her 2025 Conquer Cancer, the ASCO Foundation #YIA 🙌❗️❗️Way to represent Cedars-Sinai. Proud to serve as her mentor for this award. As a former class of 2022 ASCO #CCF #CDA recipient, I know how impactful this award will be

Huge congrats to <a href="/CSCancerCenter/">Cancer at Cedars-Sinai</a> 2nd yr heme/onc fellow Dr. Louisa Liu for her 2025 <a href="/ConquerCancerFd/">Conquer Cancer, the ASCO Foundation</a> #YIA 🙌❗️❗️Way to represent <a href="/CedarsSinai/">Cedars-Sinai</a>. Proud to serve as her mentor for this award. As a former class of 2022 <a href="/ASCO/">ASCO</a> #CCF #CDA recipient, I know how impactful this award will be
Jun Gong (@jgong15) 's Twitter Profile Photo

Dr. Elez Vall d'Hebron Vall d’Hebron Institute of Oncology (VHIO) updated results of BREAKWATER #1L #BRAFV600E MT #mCRC ➡️ PFS 12.8 mos/OS 30.3 mos FOLFOX-EC vs PFS 7. 1 mos/OS 15.1 mos SOC, impressive OS benefit even w/EC access in control arm. Activity shown for EC alone arm as well #ASCO25 OncoAlert

Dr. Elez <a href="/vallhebron/">Vall d'Hebron</a> <a href="/VHIO/">Vall d’Hebron Institute of Oncology (VHIO)</a> updated
results of BREAKWATER #1L #BRAFV600E MT #mCRC ➡️ PFS 12.8 mos/OS 30.3 mos FOLFOX-EC vs PFS 7. 1 mos/OS 15.1 mos SOC, impressive OS benefit even w/EC access in control arm. Activity shown for EC alone arm as well #ASCO25

<a href="/OncoAlert/">OncoAlert</a>
Jun Gong (@jgong15) 's Twitter Profile Photo

Dr. Strickler PhIb CodeBreak101 in 2L+ #KRASG12C MT #mCRC ➡️ n=40 at Soto 960 mg QD + standard dose FOLFIRI + pmab (50% had PD w/irino before) ORR 55% w/prior irino PD, PFS 8.2 mos, OS 15.6 mos. No new safety signals. PhIII underway CodeBreaK 301 #ASCO25 OncoAlert

Dr. Strickler PhIb CodeBreak101 in 2L+ #KRASG12C MT #mCRC ➡️ n=40 at Soto 960 mg QD + standard dose FOLFIRI + pmab (50% had PD w/irino before) ORR 55% w/prior irino PD, PFS 8.2 mos, OS 15.6 mos. No new safety signals. PhIII underway CodeBreaK 301 #ASCO25 

<a href="/OncoAlert/">OncoAlert</a>
Jun Gong (@jgong15) 's Twitter Profile Photo

Dr. Haas 5-year update of KN-564 of adj pembro vs. surveillance in localized #RCC at high-risk of recurrence ➡️ DFS and OS benefits maintained w/new landmark data shown. Survival benefits seen across key subgroups #ASCO25 OncoAlert

Dr. Haas 5-year update of KN-564 of adj pembro vs. surveillance in localized #RCC at high-risk of recurrence  ➡️ DFS and OS benefits maintained w/new landmark data shown. Survival benefits seen across key subgroups

#ASCO25
<a href="/OncoAlert/">OncoAlert</a>
Jun Gong (@jgong15) 's Twitter Profile Photo

Final results from PhIII rand CM-901 #1L #mUC cis-ineligible of nivo/ipi vs gem/carbo ➡️ primary endpoint not met, no sig diff in OS b/t arms even in PD-L1>1%, similar ORR b/t arms, higher CR rate w/nivo/ipi #ASCO25 OncoAlert

Final results from PhIII rand CM-901 #1L #mUC cis-ineligible of nivo/ipi vs gem/carbo ➡️ primary endpoint not met, no sig diff in OS b/t arms even in PD-L1&gt;1%, similar ORR b/t arms, higher CR rate w/nivo/ipi

#ASCO25
<a href="/OncoAlert/">OncoAlert</a>
Jun Gong (@jgong15) 's Twitter Profile Photo

Dr. Xu rand PhII JMT101 (potent anti-EGFR Ab) + irino/SG001(PD-1 inh) vs rego #3L #RAS/BRAF WT #mCRC ➡️ ORR 44% vs 3%, median PFS 5.7 vs 2.9 mos, in favor of triplet, benefits independent of prior anti-EGFR tx. PhIII trial planned. OS immature #ASCO25 OncoAlert

Dr. Xu rand PhII JMT101 (potent anti-EGFR Ab) + irino/SG001(PD-1 inh) vs rego #3L #RAS/BRAF WT #mCRC ➡️ ORR 44% vs 3%, median PFS 5.7 vs 2.9 mos, in favor of triplet, benefits independent of prior anti-EGFR tx.
PhIII trial planned. OS immature

#ASCO25
<a href="/OncoAlert/">OncoAlert</a>
Jun Gong (@jgong15) 's Twitter Profile Photo

Frank Sinicrope, MD plenary session PhIII #ATOMIC adj 6 mos FOLFOX +/- atezo add’l 6 mos in #MSI-H stage III #coloncancer ➡️ median F/U 37.2 mos, 3-yr DFS 86.4% vs 76.6% (HR 0.5) in favor of atezo arm, OS immature may be confounded w/post-PD IO, 2 TRAE G5 atezo arm #ASCO25 OncoAlert

<a href="/FASinicropeMD/">Frank Sinicrope, MD</a> plenary session PhIII #ATOMIC adj 6 mos FOLFOX +/- atezo add’l 6 mos in #MSI-H stage III #coloncancer ➡️ median F/U 37.2 mos, 3-yr DFS 86.4% vs 76.6% (HR 0.5) in favor of atezo arm, OS immature may be confounded w/post-PD IO, 2 TRAE G5 atezo arm

#ASCO25
<a href="/OncoAlert/">OncoAlert</a>
Jun Gong (@jgong15) 's Twitter Profile Photo

Yelena Y. Janjigian MD plenary session PhIII MATTERHORN periop FLOT +/- durva (up to 1 yr) in stage II-IVa G/GEJ adenoCA (90% PD-L1>1) ➡️ 29% reduction in PD or death, superior EFS (HR 0.71) w/durva arm. pCR 19% vs 7% (52% finished adj durva, 61% finished adj FLOT). #ASCO25 OncoAlert

<a href="/YJanjigianMD/">Yelena Y. Janjigian MD</a> plenary session PhIII MATTERHORN periop FLOT +/- durva (up to 1 yr) in stage II-IVa G/GEJ adenoCA (90% PD-L1&gt;1) ➡️ 29% reduction in PD or death, superior EFS (HR 0.71) w/durva arm. pCR 19% vs 7% (52% finished adj durva, 61% finished adj FLOT).

#ASCO25
<a href="/OncoAlert/">OncoAlert</a>